Study of LY3039478 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-04

Study Completion Date

2016-11-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study involves one dose of LY3039478 given by mouth followed by an intravenous infusion (IV) (via a tube linked to a small needle in the vein) of LY3039478. The results of this study will help to answer the following research questions:

* How much LY3039478 gets into the blood stream when given by mouth as a capsule compared to when given by an IV
* How long it takes the body to remove the study drug
* The safety of LY3039478 and any side effects that might be associated with it

Participation in the study is expected to last up to 7 weeks. There will be screening, a single study period, and a follow-up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3337641 in Healthy Participants

NCT03099148

Healthy

COMPLETED PHASE1

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100

Healthy

COMPLETED PHASE1

A Study of LY3314814 in Healthy Participants

NCT03222427

Healthy

COMPLETED PHASE1

A Study of LY3039478 in Healthy Participants

NCT02659865

Healthy

COMPLETED PHASE1

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

NCT02370485

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3039478 - Oral

LY3039478 given once, orally

Group Type EXPERIMENTAL

LY3039478

Intervention Type DRUG

Administered orally

13C 15N 2H-LY3039478 - IV

13C 15N 2H-LY3039478 given once, IV

Group Type EXPERIMENTAL

13C 15N 2H-LY3039478 IV

Intervention Type DRUG

Administered IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3039478

Administered orally

Intervention Type DRUG

13C 15N 2H-LY3039478 IV

Administered IV

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m²) inclusive

Exclusion Criteria

\- Have previously completed or withdrawn from this study or any other study investigating LY3039478, and have previously received the investigational product

• Have known allergies to LY3039478, related compounds or any components of the formulation, or history of significant atopy in the opinion of the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes